Inhibition of Polo-like kinase 1 (PLK1) synergizes with Vemurafenib in the treatment of melanoma.

(A and B) Immunoblots of cleaved-PARP (c-PARP) and p-ERK detected in A375 (A) and A375R (B) cells after 48 h treatment of either DMSO, Vemurafenib, Volasertib, or a combination of Vemurafenib and Volasertib, respectively. (C–E) Percentages of apoptotic...

全面介绍

Saved in:

书目详细资料
主要作者:	Fengyi Mao (15073242) (author)
其他作者:	Sai Wu (6096290) (author), Derek B. Allison (15141675) (author), Daheng He (9189701) (author), Yifan Kong (4458616) (author), Chaohao Li (15141681) (author), Zhiguo Li (431917) (author), Yanquan Zhang (14930570) (author), Xinyi Wang (559030) (author), Qiongsi Zhang (2818111) (author), Chi Wang (131921) (author), Xiaoqi Liu (45630) (author)
出版:	2025
主题:	Cell Biology Genetics Molecular Biology Developmental Biology Cancer Hematology Biological Sciences not elsewhere classified suppress tumor growth like kinase 1 crucial transcription factor cnc homolog 1 clinical database analysis shortened mice survival >< sup >< div >< p cutaneous melanoma based v600e </ sup patient survival pten </ ca </ ></ sup synergistic efficiency novel function negatively correlates genes involved cell cycle cancer progression cancer metabolism bach1 ), >- deficiency
标签:	添加标签没有标签, 成为第一个标记此记录!

Inhibition of Polo-like kinase 1 (PLK1) synergizes with Vemurafenib in the treatment of melanoma.

相似书籍